Lymphoma Specialized Program of Research Excellence

淋巴瘤专业卓越研究计划

• 批准号: 7244895
• 负责人: GEORGE J. WEINER
• 金额: $ 8.26万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-09-11 至 2007-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7244895
• 关键词: MHC class II antigen; clinical research; lymphoma; monoclonal antibody; neoplasm /cancer immunotherapy

The University of Iowa/Mayo Clinic Lymphoma SPORE (UI/MC SPORE) consists of 5 research projects, 4 core resources, and the Career Development and Developmental Research Program. It draws on the complementary strengths of the Holden Comprehensive Cancer Center at the University of Iowa and the Mayo Clinic Comprehensive Cancer Center. Both centers have extensive experience in lymphoma research extending from basic investigation from basic investigation through translation to the clinic of a novel anti-HLA-DR monoclonal antibody and immunostimulatory CpG ODN. Mayo Clinic strengths include expertise with clinical trials including radiommunotherapy and correlative studies utilizing clinical lymphoma samples. The interaction of two comprehensive cancer centers on the UI/MC Lymphoma SPORE will allow for the performance of translational lymphoma research that would not be possible at each center alone. The overall theme of the SPORE is that Understanding the mechanisms responsible for the anti- tumor activity of anti-lymphoma monoclonal antibody therapy enhances our ability to treat lymphoma using a variety of modalities. The translational nature of the SPORE is highlighted by the inclusion of a clinical trial or population study at the onset in each research project. Specific projects are as follows: 1) Mechanism of action of anti-HLA-DR antibody therapy 2) Effector cells and anti-lymphoma antibody therapy 3) Clinical functional imaging and anti-lymphoma therapy 4) The impact of modifying antigen expression on the radioimmunotherapy of lymphoma 5) Prognostic implications of genotypic polymorphisms in lymphoma Core resources including Biostatistics, Biospecimens, Immunology, and Clinical Trials. All units within the SPORE will work to draw on the resources of both institutions to expedite the translation of discoveries into new and better approaches to the prevention and treatment of lymphoma.

爱荷华州/马约诊所淋巴瘤孢子（UI/MC孢子）的大学由5个研究项目，4个核心资源，和职业发展和发展研究计划。它利用了爱荷华州大学霍尔顿综合癌症中心和马约诊所综合癌症中心的互补优势。这两个中心在淋巴瘤研究方面都有丰富的经验，从基础研究到新型抗HLA-DR单克隆抗体和免疫刺激性CpG ODN的临床转化。马约诊所的优势包括临床试验的专业知识，包括放射治疗和利用临床淋巴瘤样本的相关研究。UI/MC淋巴瘤孢子上的两个综合癌症中心的相互作用将允许进行翻译淋巴瘤研究，这在每个中心单独进行是不可能的。SPORE的总体主题是了解抗淋巴瘤单克隆抗体治疗的抗肿瘤活性机制，增强我们使用各种方式治疗淋巴瘤的能力。SPORE的转化性质通过在每个研究项目开始时纳入临床试验或人群研究而突出。具体项目如下：1）抗HLA-DR抗体治疗的作用机制2）效应细胞和抗淋巴瘤抗体治疗3）临床功能成像和抗淋巴瘤治疗4）修饰抗原表达对淋巴瘤放射免疫治疗的影响5）淋巴瘤基因型多态性的预后意义核心资源包括生物统计学，生物标本，免疫学和临床试验。SPORE内的所有单位将努力利用这两个机构的资源，加快将发现转化为新的和更好的方法来预防和治疗淋巴瘤。